Government-backed Generics Limiting Netherlands Pharmaceutical Market Growth
The Netherlands’ pharmaceutical market value will rise slowly from approximately $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment tool, according to research and consulting firm GlobalData.
The company’s latest report* states that the introduction of preference policies by health insurers has played a significant role in the increasing share of prescriptions dispensed as generic medicines.
Generic substitution at the pharmacy level and drugs prescribed by their International Non-proprietary Name (INN) are permitted in the Netherlands, and physicians have adopted an electronic prescribing system through which the brand name of a drug automatically converts to the INN name.
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Due to preference policies, health insurers have restricted reimbursement to certain selected groups of medicines.
“Insurers mainly prefer the reimbursement of generic drugs, unless there are financial advantages involved in reimbursing patented medicines. Otherwise, patients are only allowed the reimbursement of non-preferred drugs if there is a medical need, which must be ratified by their physician.”
Actavis, Disphar International, Mylan, Pharmachemie, Apotex and Sandoz are the major generics players in the Netherlands. According to the Dutch Foundation for Pharmaceutical Statistics, generics had a 63.3% share of all prescription medicines sold in the country in 2012.
Owide explains: “The Netherlands’ generic market has huge potential for development due to the high number of leading drugs going off-patent every year.
“However, the impact of increasing amounts of generic drugs will slow the overall growth of the country's pharmaceutical market.”
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - The Netherlands
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance